MMR vaccine may offer protection against Covid-19 complications: Scientists

In the study, published in the journal mBio, they said vaccination with MMR in immunocompetent individuals may be effective for health care workers who can easily be exposed to Covid-19

Serum institute, coronavirus, vaccine, pharma, drugs
They said these vaccines can induce
Press Trust of India Washington
2 min read Last Updated : Jun 19 2020 | 8:44 PM IST
The administration of a vaccine unrelated to the novel coronavirus, such as the one used for measles, mumps, rubella, or MMR, may serve as a preventive measure against the worst complications of Covid-19, say scientists.

Researchers, including those from the Louisiana State University in the US, said live attenuated vaccines, which are made using weakened strains of a disease-causing pathogen, provide non-specific protection against lethal infections.

They said these vaccines can induce "trained" innate immune cells for improved host responses against subsequent infections.

In the study, published in the journal mBio, they said vaccination with MMR in immunocompetent individuals may be effective for health care workers who can easily be exposed to Covid-19.

ALSO READ: Coronavirus LIVE

The researchers speculated that adults who had received the MMR vaccine in childhood likely still possess antibodies against the targeted viruses which at the very least would provide added protection against measles, mumps, and rubella for older adults.

With the added induction of the immune system's trained innate cells, they believe MMR vaccination could also provide protection against the "worst sequelae of Covid-19."

"In direct support of this concept, it was recently reported that the milder symptoms seen in the 955 sailors on the USS Roosevelt who tested positive for Covid-19 may have been a consequence of the fact that MMR vaccinations are given to all US Navy recruits," the scientists wrote in the study.

The researchers have called for a clinical trial with MMR in high-risk populations, suggesting it may provide a "low-risk high-reward" preventive measure in saving lives during the pandemic.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccine

Next Story